AstraZeneca's Ambition 2030 Strategy

AstraZeneca's Ambition 2030 Strategy

• 1. Investor Day • 2024 Ambition 2030 and beyond Pascal Soriot, CEO

• 2. Investor Day • 2024 Forward looking statements 2 In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected or targeted revenues, margins, earnings per share or other financial or other measures (including the Financial Ambition Statements described in this presentation). Although the Group believes its expectations and targets are based on reasonable assumptions and has used customary forecasting methodologies used in the pharmaceutical industry and risk-adjusted projections for individual medicines (which take into account the probability of success of individual clinical trials, based on industry-wide data for relevant clinical trials at a similar stage of development), any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group’s control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group’s commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group’s medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet regulatory or ethical expectations on environmental impact, including climate change; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property-related risks to the Group’s products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group’s financial position; the impact that global and/or geopolitical events may have, or continue to have, on these risks, on the Group’s ability to continue to mitigate these risks, and on the Group’s operations, financial results or financial condition There can be no guarantees that the conditions to the closing of the proposed transaction with Fusion will be satisfied on the expected timetable, or at all, or that “FPI-2265” (Ac225-PSMA I&T) or any combination product will receive the necessary regulatory approvals or prove to be commercially successful if approved. There can be no guarantees that the conditions to the closing of the proposed transaction with Amolyt Pharma will be satisfied on the expected timetable, or at all, or that eneboparatide (‘AZP-3601’) will receive the necessary regulatory approvals or prove to be commercially successful if approved. This presentation includes references to new molecular entities and life-cycle management programmes that are being investigated in current or future clinical trials, and as such have not been approved by any regulatory agency. For a list of new molecular entities and indications in development, see pages 7-11 of the Clinical Trials Appendix that accompanied AstraZeneca’s Q1 2024 results. Basis of AstraZeneca ambitions, forecasts and targets AstraZeneca ambitions, forecasts and targets in this presentation (the “Financial Ambition Statements”) are derived from AstraZeneca’s most recent risk-adjusted mid- and long-term plans, adjusted for developments in the business since those plans were finalised. Financial Ambition Statements presented are based on management’s risk-adjusted projections for individual medicines and individual clinical trials. Estimates for these probabilities are based on industry-wide data for relevant clinical trials in the pharmaceutical industry at a similar stage of development adjusted for management's view on the risk profile of the specific asset. The peak year revenue (PYR) potential for individual medicines referred to in this presentation are the maximum estimated Total Revenue to be recognised by AstraZeneca in a single calendar year, during the lifecycle of the medicine, and are based on management’s latest non-risk adjusted forecast estimates. Estimates are based on customary forecasting methodologies used in the pharmaceutical industry. Peak year revenue may occur in different years for each NME depending on trial outcomes, approval label, competition, launch dates and exclusivity periods, amongst other variables. The peak year revenue figures are derived from net sales at nominal values and are not risk-adjusted or time-value discounted. The development of pharmaceutical products has inherent risks given scientific experimentation and there are a range of possible outcomes in clinical results, safety, efficacy and product labelling. Clinical results may not achieve the desired product profile and competitive environment, pricing and reimbursement may have material impact on commercial revenue forecasts. By their nature, forecasts are based on a multiplicity of assumptions and actual performance in future years may vary, significantly and materially, from these assumptions. The Financial Ambition Statements in this presentation are based on Q1 2024 exchange rates; AZ undertakes no obligation to update those statements based on future currency movements

• 3. 1. AstraZeneca Company Statement, 06 May 2014. 2. Total Revenues ex-COVID from 2021 onwards. 3. Vaxzevria, Evusheld, sipavibart. Acronym definitions can be found in Glossary. Investor Day • 2024 We delivered on our Total Revenue ambition set in 2014 3 Delivered on ambition to achieve >$45bn Total Revenue by 2023 Press release issued 06 May 20141 From 2017 to 2023 AstraZeneca is targeting strong and consistent revenue growth leading to annual revenues of greater than $45 billion by 2023 “ ” Total Revenue ex-COVID ($bn)2 COVID-19 medicines3 Total Revenue ($bn) 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 $28.0 $25.7 $26.5 $24.7 $23.0 $22.5 $22.1 $24.4 $26.6 $37.4 $44.4 $45.8

• 4. Investor Day • 2024 Our strategy is consistent but dynamic 4 Science & innovation Growth & therapy area leadership Global footprint Sustainability • Invest in new technologies and modalities • Leverage global R&D network • Transform patient outcomes through novel medicines and combinations • Broad-based network • Differentiated Emerging Markets presence • Expand access, build health system resilience • Drive industry-leading climate agenda Acronym definitions can be found in Glossary.

• 5. Investor Day • 2024 5 strategic R&D centres across Europe, US and China 5 Cambridge, UK Gothenburg, Sweden Gaithersburg, MD Boston, MA – Kendall Square Shanghai, China Strategic R&D centre locations enable academic collaborations and ability to attract top-tier global talent Acronym definitions can be found in Glossary.

• 6. 1. NME ambition tracking from date of first regulatory approval, dated from November 2022. Acronym definitions can be found in Glossary. Investor Day • 2024 Strong, sustained pipeline delivery supports upgraded NME launch ambition 6 Clear momentum, now expect to Launch 20 NMEs by 20301 On track to achieve ambition with six NMEs already launched

• 7. 7 Investor Day • 2024 Now we have a new ambition to deliver $80bn in Total Revenue by 2030 with sustained growth thereafter On track to deliver mid-30s% Core operating margin by 2026 Beyond 2026, Core operating margin will be influenced by portfolio evolution, and the Company will target at least mid-30s%

• 8. Investor Day • 2024 Ambition – $80bn Total Revenue by 2030 and sustained 2030+ growth Working on “today, tomorrow and the day after” Note: Ambition to achieve $80bn in Total Revenue by 2030 is risk-adjusted, based on latest long-range plan – see ‘Forward looking statements’ slide for forward looking statement.. Medicines and assets listed reflect key contributors to 2030 Total Revenue ambition; however, this list is not exhaustive. Medicines and assets listed in alphabetical order and sorted by therapy area. 1. Amolyt Pharma acquisition remains subject to customary external clearances; all clinical development plans mentioned herein subject to deal closure. Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd), Amgen (Tezspire), Ionis (Wainua), Compugen (rilvegostomig), Merck & Co., Inc. (Lynparza). Acronym definitions can be found in Glossary. 2023 2030 $45.8bn IRA impact Loss of Exclusivity Existing portfolio Calquence Enhertu Imfinzi/Imjudo Tagrisso Truqap Airsupra Breztri Fasenra Lokelma Saphnelo Tezspire Wainua Ultomiris Launching key NMEs AZD0120 AZD0486 camizestrant Dato-DXd rilvegostomig saruparib volrustomig AZN ADCs baxdrostat dapa FDCs IVX-A12 tozorakimab efzimfotase alfa eneboparatide1 $80bn ADCs and Radioconjugates Cell therapy and T-cell engagers Gene therapy Next-generation IO bispecifics Weight management and risk factors Beyond 2030 Brilinta Farxiga Lynparza Soliris Illustrative only, not to scale 8

• 9. Investor Day • 2024 Strong growth potential 2030+ Multiple NMEs with $5bn+ Peak Year Revenue potential launching by 20301 9 1. Non-risk adjusted Peak Year Revenue opportunities ($bn). Peak revenues could occur beyond 2030. Estimated launch dates are subject to change. 2. Baxdrostat franchise including dapagliflozin combination. 3. includes fixed-dose combinations with balcinrenone and zibotentan. 4. CLDN18.2, B7H4, EGFR/cMET, FRα, GPRC5D, CD123. Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Dato-DXd), Compugen (rilvegostomig). *Includes several medicines with multi-blockbuster potential Dato-DXd TROP2 ADC | breast, lung, other camizestrant ngSERD | breast cancer volrustomig PD-1/CTLA-4 | lung, HNSCC, others rilvegostomig PD-1/TIGIT | lung, BTC, others saruparib PARPi | prostate, others baxdrostat franchise2 ASI | hypertension dapagliflozin FDCs3 SGLT2i/MRM/ETA | cardiorenal NMEs currently in Phase III NMEs currently in Phase I/II AZD0780 oPCSK9 | dyslipidaemia weight management* oGLP-1/FDCs AZD0486 CD19/CD3 | haematology AZN ADCs*,4 multiple | solid tumours, haem AZD0120 (GC012F) BCMA/CD19 | haematology

• 10. Investor Day • 2024 Investing in disruptive categories to drive 2030+ growth Weight management and risk factors Establish and lead in new weight management paradigm oGLP-1 mono and FDCs Long-acting amylin GLP-1/glucagon Next-gen IO bispecifics Replace existing PD-1/ PD-L1 inhibitors volrustomig (PD-1/CTLA-4) rilvegostomig (PD-1/TIGIT) 1Fusion Pharmaceuticals acquisition remains subject to customary external clearances; all clinical development plans mentioned herein subject to deal closure. Acronym definitions can be found in Glossary. Collaboration partners: Compugen (rilvegostomig). Gene therapy and gene editing Make cure possible for a range of rare diseases sAAVy and AAV capsid TALEN technology ADCs and Radioconjugates Replace systemic chemotherapy and radiotherapy Six clinical-stage ADCs FPI-22651 Cell therapy and T-cell engagers Develop scalable cell therapies and T-cell engagers across therapy areas AZD0120 (BCMA/CD19) AZD0486 (CD19/CD3 TCE) Solid tumour cells 10

• 11. Investor Day • 2024 Leveraging external and internal innovation to build pipeline of leading new modalities and technologies 11 NOVEL RCs1 Combo opportunities + DDR, + IO, + cell therapy Oncology Internal technologies NOVEL ADCS Six clinical-stage internal ADCs Combo opportunities + IO, + CTx Foundation in ADCs Oncology CELL THERAPY Internal technologies T-CELL ENGAGERS Internal technologies GENE THERAPY Internal technologies Oncology BioPharma Rare Disease gene therapy portfolio Oncology BioPharma Rare Disease Rare Disease 1. Fusion Pharmaceuticals acquisition remains subject to customary external clearances; all clinical development plans mentioned herein subject to deal closure. Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo

• 12. 1. Forward-years (2024E-2027E) reflect risk-adjusted estimates 2. DataHorizzon Research, estimate dated 2032; 3. Precedence Research, estimate dated 2032. Acronym definitions can be found in Glossary. Investor Day • 2024 High-value new modalities and technologies are a growing proportion of our NME pipeline 12 2021 2022 2023 2024E 2025E 2026E 2027E Chart Title Novel ADCs/RCs Cell Therapy T-Cell Engager Gene Therapy Other NME pipeline (volume of ongoing programmes)1 Cell therapy Gene therapy and editing ADCs and Radioconjugates >$20bn estimated market2 >$30bn estimated market2 ADCs >$80bn RCs >$10bn estimated market3 Novel ADCs/RCs Cell therapy T-cell engager Gene therapy Other

• 13. Investor Day • 2024 1. Includes basket or signal detection trials and fixed-dose combination programmes. Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Dato-DXd), Compugen (rilvegostomig). Pipeline combinations strengthen therapy area leadership 13 37 ongoing combination trials1 with potential to transform patient outcomes Oncology CVRM + + = Targeted ADC or RC Robust clinical portfolio Next-generation IO volrustomig • rilvegostomig Biomarker selected population Early detection Early diagnosis and biomarkers Identify targeted population + Transforming outcomes Targeting new opportunities through novel FDCs dapagliflozin FDCs address CKD • cardiorenal • cirrhosis AZD0780 (oPCSK9) and AZD5004 (oGLP-1) address dyslipidaemia and weight management Complementary assets address full spectrum of cardiomyopathy Illustrative 5-year OS, % IO bispecifics + ADC (BM+) IO bispecific + ADC Bispecific + CTx or ADC + PDx PDx ± CTx

• 14. 1. As of Q1 2024 results, dated 25 April 2024. All growth rates at CER. 2. 2021-2023 growth rates exclude COVID-19 revenues. 3. CAGRs refer to product sales volume. Acronym definitions can be found in Glossary. Investor Day • 2024 AstraZeneca Global footprint supports opportunity in the Emerging Markets 14 Emerging Markets delivering strong Total Revenue growth2 10% 16% 20% 26% 21% 41% 35% 40% 4% -1% 8% 13% 2021 2022 2023 Q1 2024 Emerging Markets EM (ex-China) China Emerging Markets 29% of Total Revenue1 Recent EM growth drivers will support growth to 20303 Diabetes | 25% 2019-2023 CAGR Rare Disease | 22% 2019-2023 CAGR COPD/Asthma | 13% 2019-2023 CAGR Oncology | 13% 2019-2023 CAGR US EU Emerging Markets ERoW 29%

• 15. Investor Day • 2024 1. Scope 1 includes emissions from the combustion of fuel and operation of facilities. Scope 2 (market-based) includes emissions from electricity, heat, steam and cooling purchased for own use. Emissions from imported electricity are calculated using the GHG Protocol Scope 2 Guidance (January 2015) requiring dual reporting using two emissions factors for each site—market-based and location-based. AstraZeneca corporate emissions reporting and targets follow the market-based approach. Bureau Veritas has provided limited assurance for 2023 sustainability activities including greenhouse gas emissions, water use and waste management. Acronym definitions can be found in Glossary. Delivering industry-leading sustainability Decoupling Total Revenue growth from Scope 1 & 2 emissions reduction 15 Total Revenue vs Scope 1 & 2 emissions1 - 100,000 200,000 300,000 400,000 500,000 600,000 700,000 0 10,000 20,000 30,000 40,000 50,000 2015 2023 Scope 1 & 2 Emissions (tCO2e) Total Revenue ($m) Total Revenue ($m) Scope 1 & 2 (tCO2e) 68% Reduction in Scope 1 &2 since 2015 Ambition Zero Carbon • 98% reduction in Scope 1 & 2 emissions by 2026 • 50% reduction in Scope 3 by 2030 Product sustainability • Reduce energy, water, material use, waste and pollution • 20% reduction in water since 2015 • 13% reduction in waste since 2015

• 16. Investor Day • 2024 2024 catalysts to date unlock significant growth Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Enhertu). ADRIATIC LAURA DESTINY-Breast06 ECHO Imfinzi potential first IO therapy in LS-SCLC Tagrisso expanding in early-stage EGFRm NSCLC Enhertu moving into 2L Breast, benefit in HER2- ultralow Calquence first BTKi to show favourable OS trend in 1L MCL Tagrisso + CTx Enhertu Ultomiris Expanding Ultomiris in neurology with NMOSD approval Tumour agnostic approval expands Enhertu in solid tumours FLAURA2 reinforces Tagrisso as TKI backbone in 1L NSCLC Positive Phase III readouts Transformative new approvals and launches Airsupra Airsupra is first ICS/SABA combination treatment for asthma 16

• 17. Investor Day • 2024 40+ Phase III trial readouts expected by end of 2025 ~$20bn potential revenue in 2030 (non-risk adjusted) from major 2024/2025 readouts1 and launches to date in 2024 1. 2024/2025 readouts include those listed within prior slide and anticipated readouts listed on this slide. 2. Amolyt Pharma acquisition remains subject to customary external clearances; all clinical development plans mentioned herein subject to deal closure. Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd), Amgen (Tezspire). Major 2024 readouts Major 2025 readouts Truqap CAPItello-281 | dPTEN mHSPC Calquence AMPLIFY | 1L CLL Fasenra RESOLUTE | COPD Enhertu DB09 | HER2+ mBC baxdrostat BaxHTN | uHTN eneboparatide1 CALYPSO | hypoparathyroidism camizestrant SERENA-6 | ESR1m HR+ mBC Dato-DXd AVANZAR | 1L NSCLC anselamimab 301/2 | AL amyloidosis Enhertu DB11 | HER2+ eBC Ultomiris TM-313 | HSCT-TMA Breztri KALOS/LOGOS | asthma 17 Dato-DXd TROPION-Breast02 | TNBC Tezspire WAYPOINT | CRwNP

• 18. 18 Investor Day • 2024 Appendix

• 19. 19 Investor Day • 2024 Glossary – 1 of 2 CLL chronic lymphocytic leukaemia cm centimetre CM cardiomyopathy cMET c-mesenchymal epithelial transition factor COPD chronic obstructive pulmonary disease CRwNP chronic rhinosinusitis with nasal polyps CSA-AKI cardiac surgery-associated acute kidney injury ctDNA circulating tumour DNA CTLA4 cytotoxic T-lymphocyte associated protein 4 CTx chemotherapy CV cardiovascular CVRM Cardiovascular, Renal and Metabolism DDR DNA damage response DGF delayed graft function DLBCL diffuse large B-cell lymphoma dnTGFb dominant-negative transforming growth factor-beta dPTEN phosphatase and tensin homolog deficient EBITDA Earnings before interest, tax, depreciation and amortisation EGFR epidermal growth factor receptor eGFR estimated glomerular filtration rate EGPA eosinophilic granulomatosis with polyangiitis EM Emerging Markets EOS eosinophil EPI epigenetics EPS earnings per share ERoW Established Rest of World ESR1 estrogen receptor alpha ESRD end stage renal disease ETA RA endothelin receptor A antagonist ETARA endothelin receptor A antagonist FDC fixed dose combination FeNO fractional exhaled nitric oxide FL Follicular lymphoma FLAP 5-lipoxygenase activating protein FRα folate receptor alpha FX foreign exchange G7 US, Japan, EU5 GA geographic atrophy GLP-1/glu glucagon-like peptide 1 receptor/glucagon dual peptide agonist GLP-1RA glucagon-like peptide 1 receptor agonist gMG generalised myasthenia gravis GN glomerulonephritis GPC3 Glypican-3 GPRC5D G protein-coupled receptor class C group 5 member D GU genitourinary GYN gynaecologic HbA1c glycated haemoglobin HCC hepatocellular carcinoma HER2 human epidermal growth factor receptor 2 HF heart failure HFrEF heart failure with reduced ejection fraction HK hyperkalaemia HLR high-level results hMPV human metapneumovirus HNSCC head and neck squamous cell carcinoma HR hazard ratio HR+ hormone receptor positive HRR homologous recombination repair HSCT-TMA hematopoietic stem cell transplantation-associated thrombotic microangiopathy i.v. intravenous IBD inflammatory bowel disease ICS inhaled corticosteroid ICU intensive care unit IgAN IgA nephropathy IIT investigated initiated trial iJAK1 inhaled Janus kinase IL-33 interleukin-33 IL-5 interleukin-5 IND investigational new drug IO Immuno-oncology IPF idiopathic pulmonary fibrosis IRA Inflation Reduction Act iTSLP inhaled thymic stromal lymphopoietin ITT intent to treat IVIg intravenous immunoglobulin 1L, 2L, 3L first-, second-, third-line 6MWT 6-minute walk test AAV adeno-associated virus ACE angiotensin-converting enzyme AChR+ acetylcholine receptor-positive ADC antibody conjugate ADsCa albumin-adjusted serum calcium AER annual exacerbation rate AEs adverse effects AGA actional genomic alteration aHUS atypical haemolytic uraemic syndrome AL amyloidosis light-chain amyloidosis AML acute myelogenous leukaemia AMR antibody mediated rejection anti-PCD anti plasma cell dyscrasia AQP4+ aquaporin-4 antibody positive ARB angiotensin receptor blockers ASCO American Society of Clinical Oncology ASI aldosterone synthase inhibitor ASO antisense oligonucleotide ATTR-CM transthyretin amyloid cardiomyopathy ATTR-PN transthyretin amyloid polyneuropathy B-ALL B-cell acute lymphoblastic leukaemia BCMA B-cell maturation antigen BRCA breast cancer gene BTC biliary tract cancer BTKi Bruton's tyrosine kinase C5 complement component 5 CAGR compound adjusted growth rate cAMR chronic antibody-medicated rejection CAR-T chimeric antigen receptor T-cells CD19 Cluster of differentiation 19 CD3 Cluster of differentiation 3 CDK4/6i cyclin-dependent kinase 4/6 inhibitor CER constant exchange rates CI confidence interval CKD chronic kidney disease CLDN 18.2 Claudin-18.2

• 20. 20 Investor Day • 2024 Glossary – 2 of 2 NST neoadjuvant systemic treatment NT-proBNP N-terminal pro-B-type natriuretic peptide NYHA New York Heart Association oGLP1 oral glucagon-like receptor peptide 1 oPCSK9 oral protein convertase subtilisin/kexin type 9 ORR overall response rate oRXFP1 oral relaxin family peptide receptor 1 OS overall survival PALB2m partner and localizer of BRCA2 PARP1 poly(ADP-ribose) polymerase-1 PARPi poly-ADP ribose polymerase inhibitor PD1 programmed cell death protein 1 PD-L1 programmed cell death ligand 1 PFS progression free survival PIK3CA phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit PK/PD pharmacokinetic/pharmacodynamic PLEX plasma exchange PN polyneuropathy PNH paroxysmal nocturnal haemoglobinuria PNH-EVH paroxysmal nocturnal haemoglobinuria with extravascular haemolysis PNPLA3 phospholipase domain-containing protein 3 PP plasmapheresis PSA prostate-specific antigen PSA50 prostate-specific antigen 50 PTEN phosphatase and TENsin homolog deleted on chromosome 10 PYR peak year revenue Q2W every 2 weeks Q4W every 4 weeks Q8W every 8 weeks QCS quantitative continuous scoring QoQ quarter on quarter R&D research and development R&I Respiratory and Immunology r/r relapsed/refractory RA rheumatoid arthritis RAGE receptor for advanced glycation end products RC radioconjugates RP2D recommended Phase II dose RSV respiratory syncytial virus s. asthma severe asthma s.c. subcutaneous SABA short acting beta agonist SBP systolic blood pressure SBRT stereotactic brain radiotherapy SC subcutaneous SG&A Selling, General and Administrative SGLT2i sodium/glucose cotransporter 2 inhibitor sK serum potassium SLE systemic lupus erythematosus SoC standard of care ST2 suppression of tumorigenicity 2 Stg. I/II/III Stage I/II/III Stg. III u/r NSCLC Stage III unresectable non-small cell lung cancer T2D type-2 diabetes T8 US, China, Japan, EU5 TCE T-cell engager tCO2e tonnes of carbon dioxide equivalent TCR T-cell receptor TDR tumour drivers and resistance TIGIT T-cell immunoreceptor with immunoglobulin and ITIM domains TIM-3 T-cell immunoglobulin and mucin domain-containing protein TKI tyrosine kinase inhibitor TNBC triple negative breast cancer TP53 tumour protein 53 Treg Regulatory T-cell TROP2 trophoblast cell surface antigen 2 TTR transthyretin u/r HTN uncontrolled or treatment resistant hypertension UACR urinary albumin/creatinine ratio ULN upper limit of normal V&I Vaccines and Immune Therapies VLP virus-like particle K+ potassium KCCQ Kansas City Cardiomyopathy Questionnaire LA amylin long-acting amylin LABA long-acting beta 2-agonists LAMA long-acting muscarinic antagonists LCM life cycle management LDL-C low-density lipoprotein cholesterol LN lupus nephritis LoE loss of exclusivity LS-SCLC limited stage small-cell lung cancer LV left ventricular mAb monoclonal antibody MASH metabolic dysfunction-associated steatohepatitis, also known as nonalcoholic steatohepatitis (NASH) MASLD metabolic dysfunction-associated steatotic liver disease mBC metastatic breast cancer MCL mantle cell lymphoma mDOR median duration of response mg/dL milligrams per decilitre MGFA Myasthenia Gravis Foundation of America mHSPC metastatic hormone sensitive prostate cancer mL millilitre MM multiple myeloma MoA mechanism of action MPO myeloperoxidase MRA mineralocorticoid receptor antagonist MRM mineralocorticoid receptor modulator n/m not material NBRx new-to-brand prescription Neo-adj neoadjuvant NF1-PN neurofibromatosis type 1-plexiform neurofibromas ngSERD next-generation oral selective estrogen receptor degrader NHA novel hormone agent NME new molecular entity NMOSD neuromyelitis optica spectrum disorder NP nasal polyps NRDL national reimbursement drug list NSCLC non-small cell lung cancer